PrimeRFP SCOUT · Federal Contract Recompete Brief

HT942726CE012Dexamethasone nanotherapeutics for traumatic — Neurohope Therapeutics, Inc

Neurohope Therapeutics, Inc holds $1.5M across 2 federal awards, concentrated at Department of Defense (DOD). Competition previously drew 3 offers. Set-aside status: SBA. Recompete timing centers on the Aug 5, 2028 PoP end — agencies typically plan 12–18 months ahead.

Defense Health Agency

Awarding office

Neurohope Therapeutics, Inc

Recipient

Aug 5, 2028

PoP end

$1.3M

Obligated

$1.3M

Potential

541715

NAICS

AN12

PSC

SBA

Set-aside

3 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Neurohope Therapeutics, Inc — $90

Contract facts

SBA

Contract numberHT942726CE012

AgencyDefense Health Agency

Awarding officeDefense Health Agency

Awarding agencyDepartment of Defense (DOD)

Funding agencyDepartment of Defense (DOD)

IncumbentNeurohope Therapeutics, Inc

CAGE03W69

UEIYH1JEE27ME68

NAICS541715

PSCAN12

Place of performanceGREENVILLE SC

Pricing typeFirm Fixed Price

Extent competedFull And Open Competition After Exclusion Of Sources

Related solicitationHQ003420RBDST

PoP startApr 6, 2026

PoP end (current)Aug 5, 2028

Obligated$1.3M

Current value$1.3M

Potential value$1.3M

DEXAMETHASONE NANOTHERAPEUTICS FOR TRAUMATIC BRAIN INJURY is a federal SBA award for Defense Health Agency held by Neurohope Therapeutics, Inc. Estimated value $1.3M ($1.3M obligated). Current period of performance ends Aug 5, 2028. Last award drew 3 bidders. Place of performance: GREENVILLE SC. Related solicitation HQ003420RBDST.

DEXAMETHASONE NANOTHERAPEUTICS FOR TRAUMATIC BRAIN INJURY

Recompete timing

Public

● Expiring in 714 days

Current PoP ends Aug 5, 2028 (714 days remaining). Agencies typically plan 12–18 months ahead — capture window opens around Feb 5, 2027.

Incumbent footprint

Public record

Neurohope Therapeutics, Inc — $1.5M obligated across 2 awards (firm-wide, all agencies).

Sole agency: Department of Defense (DOD)

Department of Defense (DOD)$1.5M · 100% of firm total

Open full company profile →

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract HT942726CE012?

HT942726CE012 (Dexamethasone nanotherapeutics for traumatic) is a Defense Health Agency award with a potential value of $1.3M, currently held by Neurohope Therapeutics, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

Which office awarded HT942726CE012?

Defense Health Agency awarded HT942726CE012 to Neurohope Therapeutics, Inc (potential $1.3M).

Who is the incumbent on HT942726CE012?

Neurohope Therapeutics, Inc is the incumbent with $1.5M across 2 related awards in SCOUT’s public footprint. The current period of performance ends Aug 5, 2028.

When does Neurohope Therapeutics, Inc’s HT942726CE012 come up for recompete?

SCOUT tracks a period-of-performance end of Aug 5, 2028. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Seen enough? Run one full capture cycle on HT942726CE012 — $90 for 90 days.

This page stays free. Pilot is the live layer: displacement scoring, recompete pipeline, Daily Brief, and SCOUT MCP for 90 days. If you already live in Claude or ChatGPT and only need live search, start MCP Explorer at $29/mo.

Start Pilot — $90

$1/day · one payment · no subscription

Use SCOUT in your AI client — $29/mo

Classify + search inside Claude, ChatGPT, Cursor

Compare plans

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Aug 1, 2026 · refreshed monthlyLatest procurement action Mar 30, 2026